MAVYRET — Net revenues

Products & Services · Net revenues

AbbVie MAVYRET — Net revenues increased by 3.8% to $324.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 11.3%, from $291.00M to $324.00M. Over 4 years (FY 2021 to FY 2025), MAVYRET — Net revenues shows a downward trend with a -6.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2016
Last reportedQ4 2025
Rolls up toTotal Revenue

How to read this metric

An increase suggests sustained market share or successful patient access strategies, while a decrease indicates potential market saturation, generic competition, or a shift in the standard of care.

Detailed definition

This metric represents the total net sales generated from the specific pharmaceutical product line used for the treatmen...

Peer comparison

Comparable to specific therapeutic product revenue lines reported by other large-cap pharmaceutical companies, often evaluated against the backdrop of patent cliffs and competitive entry.

Metric ID: abbv_segment_mavyret_net_revenues

Historical Data

19 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Value$442.00M$426.00M$427.00M$380.00M$398.00M$383.00M$380.00M$364.00M$387.00M$370.00M$309.00M$349.00M$369.00M$302.00M$291.00M$306.00M$375.00M$312.00M$324.00M
QoQ Change-3.6%+0.2%-11.0%+4.7%-3.8%-0.8%-4.2%+6.3%-4.4%-16.5%+12.9%+5.7%-18.2%-3.6%+5.2%+22.5%-16.8%+3.8%
YoY Change-10.0%-10.1%-11.0%-4.2%-2.8%-3.4%-18.7%-4.1%-4.7%-18.4%-5.8%-12.3%+1.6%+3.3%+11.3%
Range$291.00M$442.00M
CAGR-6.7%
Avg YoY Growth-5.9%
Median YoY Growth-4.7%

Frequently Asked Questions

What is AbbVie's mavyret — net revenues?
AbbVie (ABBV) reported mavyret — net revenues of $324.00M in Q4 2025.
How has AbbVie's mavyret — net revenues changed year-over-year?
AbbVie's mavyret — net revenues increased by 11.3% year-over-year, from $291.00M to $324.00M.
What is the long-term trend for AbbVie's mavyret — net revenues?
Over 4 years (2021 to 2025), AbbVie's mavyret — net revenues has grown at a -6.3% compound annual growth rate (CAGR), from $1.71B to $1.32B.
What does mavyret — net revenues mean?
The total revenue generated from sales of the company's hepatitis C treatment product.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.